Few surveys have been performed to define the characteristics and impact of breakthrough pain in the cancer population. In this cross-sectional survey of inpatients with cancer, patients responded to a structured interview (the Breakthrough Pain Questionnaire) designed to characterize breakthrough pain, and also completed measures of pain and mood (Memorial Pain Assessment Card (MPAC)), pain-related interference in function (Brief Pain Inventory (BPI)), depressed mood (Beck Depression Inventory (BDI)), and anxiety (Beck Anxiety Inventory (BAI)). Of 178 eligible patients, 164 (92.2%) met the criteria for controlled background pain. The median age was 50.6 years (range 26 to 77 years), 52% were men, and 80.6% were Caucasian. Tumor diagnoses were mixed, 75% had metastatic disease, 65% had pain caused directly by the neoplasm, and a majority had mixed nociceptive-neuropathic pain. The median Karnofsky Performance Status score was 60 (range 40 to 90). Eighty-four (51.2%) patients had experienced breakthrough pain during the previous day. The median number of episodes was six (range 1 to 60) and the median interval from onset to peak was 3 min (range 1 s to 30 min). Although almost two-thirds (61.7%) could identify precipitants (movement 20.4%; end-of-dose failure 13.2%), pain was unpredictable in a large majority (78.2%). Patients with breakthrough pain had more intense (P < 0.001) and more frequent (P < 0.01) background pain than patients without breakthrough pain. Breakthrough pain was also associated with greater pain-related functional impairment (difference in mean BPI. P < 0.001), worse mood (mood VAS, P < 0.05; BDI, P < 0.001), and more anxiety (BAI, P < 0.001). Multivariate analysis confirmed that breakthrough pain independently contributed to impaired functioning and psychological distress. These data confirm that cancer-related breakthrough pain is a prevalent and heterogeneous phenomenon. The presence of breakthrough pain is a marker of a generally more severe pain syndrome, and is associated with both pain-related functional impairment and psychological distress. The findings suggest the need for further studies of breakthrough pain and more effective therapeutic strategies.
[1]
R. Portenoy,et al.
Breakthrough pain: definition, prevalence and characteristics
,
1990,
Pain.
[2]
A. Banning,et al.
Treatment outcome in a multidisciplinary cancer pain clinic
,
1991,
Pain.
[3]
A. Beck,et al.
An inventory for measuring clinical anxiety: psychometric properties.
,
1988,
Journal of consulting and clinical psychology.
[4]
H. Thaler,et al.
Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect
,
1992,
Cancer.
[5]
J. Holland,et al.
The memorial pain assessment card. A valid instrument for the evaluation of cancer pain
,
1987,
Cancer.
[6]
A. Beck,et al.
An inventory for measuring depression.
,
1961,
Archives of general psychiatry.
[7]
C. Cleeland,et al.
Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
,
1983,
Pain.
[8]
J. Yates,et al.
Evaluation of patients with advanced cancer using the karnofsky performance status
,
1980,
Cancer.
[9]
R. Portenoy,et al.
Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study
,
1999,
PAIN.
[10]
S. Mercadante,et al.
Predictive factors in advanced cancer pain treated only by analgesics
,
1992,
Pain.
[11]
E. Bruera,et al.
A prospective multicenter assessment of the Edmonton staging system for cancer pain.
,
1995,
Journal of pain and symptom management.
[12]
R. Portenoy.
Treatment of temporal variations in chronic cancer pain.
,
1997,
Seminars in oncology.
[13]
Katherine R. Edwards,et al.
When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function
,
1995,
Pain.